Avalo Therapeutics (AVTX) Enterprise Value (2014 - 2026)
Avalo Therapeutics (AVTX) posted Enterprise Value of -$57.2 million for Q1 2026, up 41.88% on a QoQ basis from -$98.3 million in Q4 2025, and down 92080.65% year-over-year from N/an in Q1 2025.
Avalo Therapeutics (AVTX) Enterprise Value (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Enterprise Value history runs 13 years deep, the most recent figure standing at -$57.2 million for Q1 2026.
- Quarterly Enterprise Value fell 92080.65% year-over-year to -$57.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$57.2 million (down 92080.65% YoY) and the FY2025 annual result came in at -$98.3 million, up 26.91% from the prior year.
- Enterprise Value was -$57.2 million for Q1 2026 at Avalo Therapeutics, up from -$98.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$4000.0 in Q1 2024 and bottomed at -$134.5 million in Q4 2024.
- A 5-year average of -$37.9 million and a median of -$13.4 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value soared 99.98% — and 2026, when it tumbled 92080.65%.
- Avalo Therapeutics' Enterprise Value stood at -$15000.0 in 2022, then plunged by 49333.33% to -$7.4 million in 2023, then plunged by 1714.51% to -$134.5 million in 2024, then advanced by 26.91% to -$98.3 million in 2025, then jumped by 41.88% to -$57.2 million in 2026.
- Business Quant data shows AVTX's Enterprise Value at -$57.2 million in Q1 2026, -$98.3 million in Q4 2025, and -$84.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | -57.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.15 Mn |
| Dec 31, 2025 | -98.34 Mn |
| Sep 30, 2025 | -84.74 Mn |
| Jun 30, 2025 | -70.99 Mn |
| Mar 31, 2025 | -62,000.00 |
| Dec 31, 2024 | -134.55 Mn |
| Sep 30, 2024 | -81.86 Mn |
| Mar 31, 2024 | -4,000.00 |
| Dec 31, 2023 | -7.42 Mn |
| Sep 30, 2023 | -10.18 Mn |
| Jun 30, 2023 | -6.31 Mn |
| Mar 31, 2023 | -16.69 Mn |
| Dec 31, 2022 | -15,000.00 |
| Sep 30, 2022 | -53,000.00 |
| Jun 30, 2022 | -14,000.00 |
| Mar 31, 2022 | -38.47 Mn |
| Dec 31, 2021 | -51,000.00 |
| Sep 30, 2021 | -164,000.00 |
| Jun 30, 2021 | -40.44 Mn |
| Mar 31, 2021 | -38.29 Mn |